Coherus Biosciences | CHRS - Des Atouts





Des Atouts Changement Date
AbbVie USD 135.12B 1.35B 2026-06
Acadia Pharmaceuticals USD 1.74B 137.67M 2026-06
Akebia Therapeutics USD 349.66M 12.86M 2026-06
ALKERMES USD 4.39B 135.05M 2026-06
Alnylam Pharmaceuticals USD 5.56B 429.22M 2026-06
Amarin USD 624.36M 21.4M 2026-06
Amgen USD 95.64B 3.14B 2026-06
Baxter International USD 19.79B 55M 2026-06
Biogen USD 32.09B 2.6B 2026-06
BioMarin Pharmaceutical USD 11.72B 3.13B 2026-06
Bristol-Myers Squibb USD 87.63B 1.16B 2026-06
Coherus Biosciences USD 191.18M 74.84M 2026-06
Eli Lilly USD 142.28B 25.71B 2026-06
Fujifilm JPY 6.05T 170.69B 2026-03
Gilead Sciences USD 49.36B 6.92B 2026-06
Ironwood Pharmaceuticals USD 434.57M 37.66M 2026-03
Merck USD 129.8B 1.12B 2026-06
Myriad Genetics USD 638.9M 34.8M 2026-06
Pacira USD 1.24B 35.44M 2026-06
Perrigo USD 7.61B 373.8M 2026-06
Pfizer USD 201.13B 6.49B 2026-06
PTC Therapeutics USD 3.25B 381.37M 2026-06
Regeneron Pharmaceuticals USD 41.73B 861.8M 2026-06
Sarepta Therapeutics USD 3.19B 9.58M 2026-06
Teva Pharmaceutical Industries USD 39.86B 183M 2026-06
Vertex Pharmaceuticals USD 27.42B 938.9M 2026-06
Xencor USD 724.96M 11.89M 2026-06
Zoetis USD 15.08B 77M 2026-06